iwNHL 2018 Session II
Novel Diagnostics & Biomarkers
In session II of iwNHL 2018, Ryan Wilcox, MD, Nicolas Ortonne, MD, PhD, and Scott Rodig, MD, PhD, discuss markers and diagnostics in T-cell lymphoma as well as targetable genetic alterations in diffuse large B-cell lymphoma.
Presentations
PTCL; How to Optimise the Best Predictive Biomarkers
Ryan Wilcox
University of Michigan Rogel Cancer Center, Ann Arbor, MI
University of Michigan Rogel Cancer Center, Ann Arbor, MI
22 September, 2018
Ryan Wilcox, MD, from University of Michigan Rogel Cancer Center, Ann Arbor, MI, talks about predictive biomarkers in peripheral T-cell lymphoma (PTCL).
Biomarkers for Diagnosis and Treatment of Cutaneous T-Cell Lymphomas
Nicolas Ortonne
Henri Mondor University Hospital, Créteil, France
Henri Mondor University Hospital, Créteil, France
22 September, 2018
Nicolas Ortonne, MD, PhD, from Henri Mondor University Hospital, Créteil, France, highlights the importance of identifying clinical markers that allow early diagnosis to direct therapy in cutaneous T-cell lymphomas.
Predictive Biomarkers That Help Stratify Responders to Immunotherapies
Scott Rodig
Harvard Medical School, Boston, MA
Harvard Medical School, Boston, MA
22 September, 2018
Scott Rodig, MD, PhD, from Harvard Medical School, Boston, MA, talks about the immune microenvironment in Hodgkin and non-Hodgkin lymphoma.
